HC Wainwright Reaffirms Buy Rating for Entrada Therapeutics (NASDAQ:TRDA)

HC Wainwright reaffirmed their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA - Free Report) in a report released on Monday morning,Benzinga reports. They currently have a $20.00 target price on the stock. HC Wainwright also issued estimates for Entrada Therapeutics' Q1 2025 earnings at ($0.92) EPS, Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($1.12) EPS and FY2025 earnings at ($4.11) EPS.

TRDA has been the topic of several other research reports. Roth Mkm assumed coverage on shares of Entrada Therapeutics in a report on Thursday, December 5th. They set a "buy" rating and a $29.00 price objective on the stock. Roth Capital upgraded shares of Entrada Therapeutics to a "strong-buy" rating in a research note on Thursday, December 5th.

Entrada Therapeutics Stock Performance

TRDA traded down $0.28 during trading on Monday, hitting $7.75. The stock had a trading volume of 71,752 shares, compared to its average volume of 118,731. The stock has a 50 day simple moving average of $11.66 and a two-hundred day simple moving average of $15.24. The company has a market capitalization of $291.17 million, a PE ratio of 4.84 and a beta of -0.14. Entrada Therapeutics has a twelve month low of $7.40 and a twelve month high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The firm had revenue of $12.25 million during the quarter, compared to analysts' expectations of $11.95 million. On average, equities research analysts anticipate that Entrada Therapeutics will post 1.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new stake in Entrada Therapeutics in the fourth quarter valued at approximately $36,000. BNP Paribas Financial Markets acquired a new stake in Entrada Therapeutics during the 4th quarter valued at approximately $57,000. Virtus ETF Advisers LLC purchased a new stake in shares of Entrada Therapeutics in the 4th quarter valued at $68,000. AlphaQuest LLC acquired a new stake in shares of Entrada Therapeutics in the fourth quarter worth $70,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Entrada Therapeutics by 53,455.6% during the fourth quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock worth $83,000 after purchasing an additional 4,811 shares during the last quarter. 86.39% of the stock is owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.